Base de dados : MEDLINE
Pesquisa : D02.455.426.559.847.117.050 [Categoria DeCS]
Referências encontradas : 893 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 90 ir para página                         

  1 / 893 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27864793
[Au] Autor:Baran A; Swiderska M; Bacharewicz-Szczerbicka J; Mysliwiec H; Flisiak I
[Ad] Endereço:Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St, 15-540, Bialystok, Poland. aannabaran@wp.pl.
[Ti] Título:Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis.
[So] Source:Lipids;52(1):51-60, 2017 Jan.
[Is] ISSN:1558-9307
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Psoriasis is associated with metabolic syndrome and cardiovascular disease. Fatty acid-binding proteins (FABP) have been recognized as predictors of these systemic disorders. The aim of this study was to assess correlations between levels of serum heart and adipocyte fatty acid-binding proteins (FABP3, FABP4) and disease severity, indicators of inflammation or metabolic disturbances, and topical treatment in psoriatic patients. Thirty-seven patients with relapse of plaque-type psoriasis and 16 healthy volunteers were recruited. Blood samples were collected before and after 14 days of therapy. Serum FABP concentrations were examined by enzyme-linked immunosorbent assay for correlation with Psoriasis Area and Severity Index (PASI), body mass index (BMI), inflammatory or metabolic parameters, and treatment used. The median FABP4 serum levels were significantly increased (p = 0.038) in psoriatic patients, while FABP3 levels did not differ (p = 0.47) compared to the controls. No significant correlations were noted between the proteins and PASI, C-reactive protein (CRP), BMI, or levels of glucose or lipids. FABP3 significantly correlated with white blood count (p = 0.03) and aspartate aminotransferase (p = 0.04). After topical treatment, there was no significant change in serum FABP3 [11.5 (4.9-30.3) vs. 12.9 (3.5-30.3) ng/ml] (p = 0.96), whereas FABP4 was decreased [27,286 (20,344-32,257) vs. 23,034 (18,320-29,874) pg/ml] (p = 0.12), losing its basal significance. FABP4 may be a marker of psoriasis, and FABP3 may be associated with inflammation or liver disorders in psoriatic patients. FABP do not appear to be useful for determining disease severity or the effectiveness of antipsoriatic treatment.
[Mh] Termos MeSH primário: Antralina/administração & dosagem
Proteínas de Ligação a Ácido Graxo/sangue
Psoríase/tratamento farmacológico
Ácido Salicílico/administração & dosagem
[Mh] Termos MeSH secundário: Administração Tópica
Adulto
Idoso
Idoso de 80 Anos ou mais
Antralina/farmacologia
Proteína 3 Ligante de Ácido Graxo
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Psoríase/metabolismo
Ácido Salicílico/farmacologia
Índice de Gravidade de Doença
Resultado do Tratamento
Regulação para Cima/efeitos dos fármacos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (FABP3 protein, human); 0 (FABP4 protein, human); 0 (Fatty Acid Binding Protein 3); 0 (Fatty Acid-Binding Proteins); O414PZ4LPZ (Salicylic Acid); U8CJK0JH5M (Anthralin)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161120
[St] Status:MEDLINE
[do] DOI:10.1007/s11745-016-4211-4


  2 / 893 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27267830
[Au] Autor:Tankeo SB; Damen F; Sandjo LP; Celik I; Tane P; Kuete V
[Ad] Endereço:Department of Biochemistry, Faculty of Science, University of Dschang, Cameroon.
[Ti] Título:Antibacterial activities of the methanol extracts, fractions and compounds from Harungana madagascariensis Lam. ex Poir. (Hypericaceae).
[So] Source:J Ethnopharmacol;190:100-5, 2016 Aug 22.
[Is] ISSN:1872-7573
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:ETHNOPHARMACOLOGICAL RELEVANCE: Harungana madagascariensis Lam. ex Poir. (Hypericaceae) is used in folk medicine to treat a variety of human ailments, mainly antibacterial, antifungal, antiviral and viral infections. In the present study, the methanol extract from the leaves (HML) and bark (HMB) of this plant as well as fractions (HMBa-c), sub-fractions (HMBa1-5) and compounds isolated from HMBa and HMBb namely betulinic acid (1), madagascin (2), ferruginin A (3) and Kaempferol-3-O-ß-d-glucopyranoside (4) were tested for their antimicrobial activities against a panel of 28 g-negative bacteria including multidrug resistant (MDR) phenotypes. MATERIALS AND METHODS: The broth microdilution method was used to determine the minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of the above samples; column chromatography was used for the fractionation and purification of the bark extract whilst the chemical structures of compounds were determined using spectroscopic techniques. RESULTS: Crude extract HMB together with fraction HMBa and sub-fraction HMBa3 were active on the 28 tested bacterial strains. HML as well as fractions HMBb, HMBc and sub-fractions HMBa1, HMBa2, HMBa4 and HMBa5 were selectively active. MIC values below or equal to 1024µg/mL were recorded with these samples on 92.9% (for HML and HMBa 4), 82.1% (for HMBb), 78.6% (for HMBa2), 50.0% (for HMBa5) and 42.9% (for HMBc) tested bacteria. For crude material, the lowest MIC value below 8µg/mL was obtained with HMB against Escherichia coli ATCC10536 and W3110 strains, and with sub-fraction HMBa3 against Klebsiella pneumoniae K2 strains. MIC values below 10µg/mL were recorded with compound 3 against E. coli ATCC10536, Enterobacter aerogenes ATCC13048 and EA294, Pseudomonas aeruginosa PA01, K. pneumoniae K2 and Kp55 and Enterobacter cloacae BM67. CONCLUSIONS: Harungana madagascariensis is a potential source of antimicrobial drugs to fight against MDR bacteria. The anthranol 3 is the main antibacterial constituents of the bark of the plant. HMB and compound 3 deserve further investigations to develop natural drug to combat Gram-negative bacteria and otherwise MDR phenotypes.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Bactérias/efeitos dos fármacos
Clusiaceae/química
Metanol/química
Extratos Vegetais/farmacologia
Solventes/química
[Mh] Termos MeSH secundário: Antralina/isolamento & purificação
Antralina/farmacologia
Antraquinonas/isolamento & purificação
Antraquinonas/farmacologia
Antibacterianos/química
Antibacterianos/isolamento & purificação
Bactérias/crescimento & desenvolvimento
Farmacorresistência Bacteriana Múltipla
Hemiterpenos/isolamento & purificação
Hemiterpenos/farmacologia
Quempferóis/isolamento & purificação
Quempferóis/farmacologia
Testes de Sensibilidade Microbiana
Estrutura Molecular
Fitoterapia
Casca de Planta
Extratos Vegetais/química
Extratos Vegetais/isolamento & purificação
Folhas de Planta
Plantas Medicinais
Triterpenos/isolamento & purificação
Triterpenos/farmacologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (3-isopentenyloxyemodin); 0 (Anthraquinones); 0 (Anti-Bacterial Agents); 0 (Hemiterpenes); 0 (Kaempferols); 0 (Plant Extracts); 0 (Solvents); 0 (Triterpenes); 4G6A18707N (betulinic acid); U8CJK0JH5M (Anthralin); Y4S76JWI15 (Methanol)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170418
[Lr] Data última revisão:
170418
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160609
[St] Status:MEDLINE


  3 / 893 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27074696
[Au] Autor:Stein Gold LF
[Ad] Endereço:Director of Dermatology Research Henry Ford Health System Detroit, Michigan.
[Ti] Título:Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence.
[So] Source:Semin Cutan Med Surg;35(2 Suppl 2):S36-44; quiz S45, 2016 Mar.
[Is] ISSN:1085-5629
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Psoriasis is a chronic disease that has a substantial effect on quality of life of patients and often needs long-term treatment. Topical treatments for psoriasis include corticosteroids, vitamin D derivatives, tazarotene, anthralin, tacrolimus, pimecrolimus, and newer formulations of tar. Although many of these treatments are effective, they must be prescribed appropriately and used consistently for a period of weeks to months before clinical evidence of improvement can be seen and patients perceive that the treatment is working. As such, medication dosage/schedule, choice of vehicle, and especially patient adherence to medication are key factors for a treatment to be effective. Addressing patient preferences about treatments and concerns about treatment-related toxicities and managing their expectations represent additional aspects of patient care. Therapies such as calcipotriene and betamethasone dipropionate (Cal/BD) fixed combination foam and new drugs and vehicles continuously enhance the treatment landscape for psoriasis. Because adherence to topical treatment can be a major difficulty, keeping the treatment regimen simple and using new and sophisticated treatment vehicles that are acceptable to patients can likely improve treatment outcomes.
[Mh] Termos MeSH primário: Fármacos Dermatológicos/administração & dosagem
Cooperação do Paciente
Psoríase/tratamento farmacológico
Qualidade de Vida
[Mh] Termos MeSH secundário: Administração Cutânea
Antralina/administração & dosagem
Betametasona/administração & dosagem
Betametasona/análogos & derivados
Calcitriol/administração & dosagem
Calcitriol/análogos & derivados
Fármacos Dermatológicos/uso terapêutico
Combinação de Medicamentos
Quimioterapia Combinada
Medicina Baseada em Evidências
Glucocorticoides/administração & dosagem
Seres Humanos
Ácidos Nicotínicos/administração & dosagem
Veículos Farmacêuticos/administração & dosagem
Guias de Prática Clínica como Assunto
Psoríase/diagnóstico
Índice de Gravidade de Doença
Tacrolimo/administração & dosagem
Tacrolimo/análogos & derivados
Resultado do Tratamento
Vitamina D/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Drug Combinations); 0 (Glucocorticoids); 0 (Nicotinic Acids); 0 (Pharmaceutical Vehicles); 1406-16-2 (Vitamin D); 143NQ3779B (calcipotriene); 7KYV510875 (pimecrolimus); 81BDR9Y8PS (tazarotene); 826Y60901U (betamethasone-17,21-dipropionate); 9842X06Q6M (Betamethasone); FXC9231JVH (Calcitriol); U8CJK0JH5M (Anthralin); WM0HAQ4WNM (Tacrolimus)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:160414
[Lr] Data última revisão:
160414
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160414
[St] Status:MEDLINE
[do] DOI:10.12788/j.sder.2016.006


  4 / 893 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26895458
[Au] Autor:Mysliwiec H; Mysliwiec P; Baran A; Flisiak I
[Ad] Endereço:Department of Dermatology and Venereology, Medical University of Bialystok, Bialystok, Poland. Electronic address: hanna.mysliwiec@gmail.com.
[Ti] Título:Dithranol treatment of plaque-type psoriasis increases serum TNF-like weak inducer of apoptosis (TWEAK).
[So] Source:Adv Med Sci;61(2):207-211, 2016 Sep.
[Is] ISSN:1898-4002
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:PURPOSE: TNF-like weak inducer of apoptosis (TWEAK) mediates not only apoptosis, but also inflammation, cell growth and angiogenesis. The role of TWEAK in psoriasis remains unknown. The aim of the study was to assess serum levels of TWEAK in psoriatic patients before and after topical treatment with dithranol in relation to the clinical activity of the disease. MATERIAL AND METHODS: Serum samples were collected from 40 patients with plaque type psoriasis before and after topical treatment with dithranol. The concentrations of serum TWEAK were measured by ELISA and next compared with 16 healthy controls. The data were analyzed with respect to Psoriasis Area and Severity Index (PASI). RESULTS: Baseline serum TWEAK concentrations of psoriatic patients (685±166pg/ml) were significantly greater compared to healthy controls (565±110pg/ml). Topical treatment resulted in further increase in serum TWEAK (749±179pg/ml; p<0.01). In case of patients with initial serum TWEAK concentrations above the median, PASI after topical treatment was lower compared to the individuals with initial TWEAK below the median. CONCLUSION: According to the study, serum Tweak was increased in psoriasis patients compared with controls. Moreover, dithranol topical treatment caused further increase in serum TWEAK. Also, a higher effectiveness of topical treatment was observed in case of patients with higher initial TWEAK concentrations. The results suggest a potential role of TWEAK in psoriasis therapy.
[Mh] Termos MeSH primário: Antralina/uso terapêutico
Psoríase/sangue
Psoríase/tratamento farmacológico
Fatores de Necrose Tumoral/sangue
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Antralina/farmacologia
Estudos de Casos e Controles
Citocina TWEAK
Feminino
Seres Humanos
Contagem de Leucócitos
Masculino
Meia-Idade
Índice de Gravidade de Doença
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cytokine TWEAK); 0 (TNFSF12 protein, human); 0 (Tumor Necrosis Factors); U8CJK0JH5M (Anthralin)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160220
[St] Status:MEDLINE


  5 / 893 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26841099
[Au] Autor:Archid R; Duerr HP; Patzelt A; Philipp S; Röwert-Huber HJ; Ulrich M; Meinke MC; Knorr F; Lademann J
[Ad] Endereço:Department of Dermatology, Venereology and Allergology, Charitx00E9; - Universitx00E4;tsmedizin Berlin, Berlin, Germany.
[Ti] Título:Relationship between Histological and Clinical Course of Psoriasis: A Pilot Investigation by Reflectance Confocal Microscopy during Goeckerman Treatment.
[So] Source:Skin Pharmacol Physiol;29(1):47-54, 2016.
[Is] ISSN:1660-5535
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Alterations of the skin microvasculature are known to play an important role in the development and maintenance of psoriatic skin lesions. In this study, we investigated lesional skin in 11 psoriatic patients during a modified Goeckerman treatment using reflectance confocal microscopy (RCM) to study the relationship between clinical clearance and histological normalization of psoriatic skin and the significance of histological abnormalities on the course of disease. The treatment regimen resulted in a significant reduction of the Psoriasis Area and Severity Index (PASI) as well as capillary and papillary diameters (p < 0.0001). The capillary and papillary diameters were still enlarged when compared to those in normal skin (p < 0.001). Capillary and papillary diameters correlated with each other prior to and after treatment (correlation coefficient = 0.63 and 0.64, p = 0.01 and 0.002, respectively) but not with the PASI. Capillary and papillary diameters after treatment and percentage reduction of the PASI during treatment seemed to be better predictors for the clinical course of relapse than the PASI after treatment. These findings make the subclinical changes of psoriatic skin vessels and dermal papillae a legitimate target for treatment. Further investigations of a large group of patients are needed to evaluate the potential of RCM findings as successor of the PASI in the monitoring of psoriasis.
[Mh] Termos MeSH primário: Psoríase/patologia
Psoríase/terapia
Pele/patologia
[Mh] Termos MeSH secundário: Antralina/uso terapêutico
Capilares/patologia
Capilares/fisiologia
Óleo de Rícino/uso terapêutico
Alcatrão/uso terapêutico
Feminino
Seres Humanos
Masculino
Microscopia Confocal
Meia-Idade
Projetos Piloto
Psoríase/fisiopatologia
Ácido Salicílico/uso terapêutico
Sais/uso terapêutico
Índice de Gravidade de Doença
Pele/irrigação sanguínea
Terapia Ultravioleta
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Salts); 0 (brine); 8001-79-4 (Castor Oil); 8007-45-2 (Coal Tar); O414PZ4LPZ (Salicylic Acid); U8CJK0JH5M (Anthralin)
[Em] Mês de entrada:1611
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160204
[St] Status:MEDLINE
[do] DOI:10.1159/000443211


  6 / 893 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26727375
[Au] Autor:Johnson OO; Zhao M; Gunn J; Santarsiero BD; Yin ZQ; Ayoola GA; Coker HA; Che CT
[Ad] Endereço:Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago , Chicago, Illinois 60612, United States.
[Ti] Título:α-Glucosidase Inhibitory Prenylated Anthranols from Harungana madagascariensis.
[So] Source:J Nat Prod;79(1):224-9, 2016 Jan 22.
[Is] ISSN:1520-6025
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Four new prenylated anthranols, harunganols C-F (1-4), along with kenganthranol A (5), harunganin (6), and ferruginin A (7), were identified from the leaves of Harungana madagascariensis. The structures of compounds 2, 5, and 7 were confirmed by single-crystal X-ray diffraction analysis. Compound 1 is a unique symmetrical anthranol dimer connected via a CH2 group. Compound 4 possesses a unique C-10 hemiketal group. All anthranols were evaluated for their α-glucosidase inhibitory activities. They displayed a higher potency compared to acarbose except for 3 and 4. In particular, harunganol C (1) showed an IC50 value of 1.2 µM.
[Mh] Termos MeSH primário: Antralina/isolamento & purificação
Antralina/farmacologia
Clusiaceae/química
Inibidores de Glicosídeo Hidrolases/isolamento & purificação
Inibidores de Glicosídeo Hidrolases/farmacologia
alfa-Glucosidases/efeitos dos fármacos
[Mh] Termos MeSH secundário: Antralina/química
Inibidores de Glicosídeo Hidrolases/química
Concentração Inibidora 50
Estrutura Molecular
Nigéria
Folhas de Planta/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Glycoside Hydrolase Inhibitors); EC 3.2.1.20 (alpha-Glucosidases); U8CJK0JH5M (Anthralin)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:160122
[Lr] Data última revisão:
160122
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160105
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jnatprod.5b00924


  7 / 893 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26708535
[Au] Autor:Gniadecki R
[Ad] Endereço:Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark. r.gniadecki@gmail.com.
[Ti] Título:Next-generation antipsoriatic drugs: small molecules join.
[So] Source:Br J Dermatol;173(6):1355-6, 2015 Dec.
[Is] ISSN:1365-2133
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Antralina
Fármacos Dermatológicos/uso terapêutico
[Mh] Termos MeSH secundário: Seres Humanos
Psoríase/tratamento farmacológico
[Pt] Tipo de publicação:COMMENT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dermatologic Agents); U8CJK0JH5M (Anthralin)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:151228
[Lr] Data última revisão:
151228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151229
[St] Status:MEDLINE
[do] DOI:10.1111/bjd.14249


  8 / 893 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26515039
[Au] Autor:Bariamis SE; Magoulas GE; Grafanaki K; Pontiki E; Tsegenidis T; Athanassopoulos CM; Maroulis G; Papaioannou D; Hadjipavlou-Litina D
[Ad] Endereço:Department of Chemistry, School of Natural Sciences, University of Patras, 26504 Patras, Greece.
[Ti] Título:Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
[So] Source:Bioorg Med Chem;23(22):7251-63, 2015 Nov 15.
[Is] ISSN:1464-3391
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Selective alkylation of the antipsoriatic drug dithranol (DTR) at C-10 with tert-butyl bromoacetate, followed by acid-mediated deprotection, produced the corresponding carboxylic acid 4 which was coupled with selectively protected polyamines (PAs), such as putrescine (PUT), spermidine (SPD) and spermine (SPM), dopamine and aliphatic amines and substituted benzylamines producing a series of DTR-PA hybrids, after acid-mediated deprotection, as well as simple amides. The compounds were tested as antioxidants and inhibitors of lipoxygenase (LOX). The amides 4,4'-dimethoxybenzhydrylamide 13 (86% and 95%), 2,4-dimethoxybenzylamide 12 (87% and 81%) and dodecylamide 9 (98% and 74%), and the hybrid DTR-SPM (7) (93% and 87%), showed the highest antioxidant activity in the DPPH and AAPH assays, whereas the most potent inhibitors of LOX were amide 13 (IC50=7 µM), the benzylamide 10 (IC50=7.9 µM) and the butylamide 8 (IC50=10 µM). Molecular binding studies showed that binding of these derivatives into the hydrophobic domain blocks approach of substrate to the active site, inhibiting soybean LOX. Amide 13 presented the highest anti-inflammatory activity (79.7%). The DTR moiety was absolutely necessary for securing high anti-inflammatory potency. Ethyl ester 3 (IC50=0.357 µM) and the amides 9 (IC50=0.022 µM) and 13 (IC50=0.56 µM) exhibited higher antiproliferative activity than DTR (IC50=0.945 µM) on HaCaT keratinocytes whereas amide 13 generally presented better cytocompatibility. Amide 13 is a very promising lead compound for further development as an anti-inflammatory and antiproliferative agent.
[Mh] Termos MeSH primário: Antralina/síntese química
Antralina/farmacologia
Queratinócitos/efeitos dos fármacos
[Mh] Termos MeSH secundário: Amidas/química
Animais
Antralina/química
Antralina/uso terapêutico
Anti-Inflamatórios/síntese química
Anti-Inflamatórios/farmacologia
Anti-Inflamatórios/uso terapêutico
Antioxidantes/síntese química
Antioxidantes/farmacologia
Antioxidantes/uso terapêutico
Sítios de Ligação
Carragenina/toxicidade
Linhagem Celular
Proliferação Celular/efeitos dos fármacos
Sobrevivência Celular/efeitos dos fármacos
Edema/etiologia
Edema/prevenção & controle
Seres Humanos
Peroxidação de Lipídeos/efeitos dos fármacos
Lipoxigenase/química
Lipoxigenase/metabolismo
Inibidores de Lipoxigenase/síntese química
Inibidores de Lipoxigenase/química
Inibidores de Lipoxigenase/farmacologia
Simulação de Acoplamento Molecular
Poliaminas/química
Ratos
Feijão de Soja/enzimologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Amides); 0 (Anti-Inflammatory Agents); 0 (Antioxidants); 0 (Lipoxygenase Inhibitors); 0 (Polyamines); 9000-07-1 (Carrageenan); EC 1.13.11.12 (Lipoxygenase); U8CJK0JH5M (Anthralin)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:151107
[Lr] Data última revisão:
151107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151031
[St] Status:MEDLINE


  9 / 893 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26513076
[Au] Autor:Painsi C; Patscheider M; Inzinger M; Lange-Asschenfeldt B; Quehenberger F; Wolf P
[Ad] Endereço:Department of Dermatology, Medical University of Graz, Graz, Austria.
[Ti] Título:Patient perspectives on treating psoriasis with classic inpatient dithranol therapy: a retrospective patient survey.
[So] Source:J Dtsch Dermatol Ges;13(11):1156-63, 2015 Nov.
[Is] ISSN:1610-0387
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Evidence of the efficacy of dithranol and patient perspectives on the treatment is scant. PATIENTS AND METHODS: Using a telephone interview survey, we collected retrospective data from 63 patients (41 men [65.1 %] and 22 women [34.9 %]) who had been treated with classic inpatient dithranol (CID). PsoRA (www.psoriasisregistry.at) was used to obtain clinical data and treatment responses, which were then correlated with the interview responses. RESULTS: Fifty-two (82.5 %) patients achieved a PASI75 and 51 (81 %) a PASI90 response within a median of 12.5 (range: 3 to 25) days. Ten out of twelve (83 %) patients showed a satisfactory response to CID (PASI75 or greater reduction) despite the fact that they had previously failed to adequately respond to methotrexate, oral retinoids, cyclosporine, or ustekinumab. Overall, patients recalled a median recurrence-free interval of four (95 % CI: 3-9) months after responding to CID, which was positively correlated with the patients' recommendation of (p = 0.018) and their overall high satisfaction with the treatment (p = 0.012). CONCLUSIONS: Despite the known limitations of CID, this survey indicates that dithranol remains a highly efficacious and valuable treatment option as induction therapy in psoriasis. CID can be effective in patients who have failed to respond to systemic therapy, including traditional agents and biologics.
[Mh] Termos MeSH primário: Antralina/uso terapêutico
Participação do Paciente/estatística & dados numéricos
Satisfação do Paciente/estatística & dados numéricos
Psoríase/tratamento farmacológico
Psoríase/psicologia
Qualidade de Vida/psicologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Distribuição por Idade
Idoso
Áustria/epidemiologia
Fármacos Dermatológicos/uso terapêutico
Feminino
Pesquisas sobre Serviços de Saúde
Hospitalização/estatística & dados numéricos
Seres Humanos
Masculino
Meia-Idade
Participação do Paciente/psicologia
Prevalência
Psoríase/epidemiologia
Estudos Retrospectivos
Fatores de Risco
Distribuição por Sexo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dermatologic Agents); U8CJK0JH5M (Anthralin)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:151030
[Lr] Data última revisão:
151030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151030
[St] Status:MEDLINE
[do] DOI:10.1111/ddg.12820


  10 / 893 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
[PMID]:26371098
[Au] Autor:Spano F; Donovan JC
[Ad] Endereço:Dermatology resident at the University of Ottawa in Ontario.
[Ti] Título:Alopecia areata: Part 2: treatment.
[So] Source:Can Fam Physician;61(9):757-61, 2015 Sep.
[Is] ISSN:1715-5258
[Cp] País de publicação:Canada
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To provide family physicians with a background understanding of the therapeutic regimens and treatment outcomes for alopecia areata (AA), as well as to help identify those patients for whom dermatologist referral might be required. SOURCES OF INFORMATION: PubMed was searched for relevant articles regarding the treatment of AA. MAIN MESSAGE: Alopecia areata is a form of autoimmune hair loss affecting both children and adults. While there is no associated mortality with the disease, morbidity from the psychological effects of hair loss can be devastating. Upon identification of AA and the disease subtype, an appropriate therapeutic regimen can be instituted to help halt hair loss or possibly initiate hair regrowth. First-line treatment involves intralesional triamcinolone with topical steroids or minoxidil or both. Primary care physicians can safely prescribe and institute these treatments. More advanced or refractory cases might require oral immunosuppressants, topical diphenylcyclopropenone, or topical anthralin. Eyelash loss can be treated with prostaglandin analogues. Those with extensive loss might choose camouflaging options or a hair prosthesis. It is important to monitor for psychiatric disorders owing to the profound psychological effects of hair loss. CONCLUSION: Family physicians will encounter many patients experiencing hair loss. Recognition of AA and an understanding of the underlying disease process will allow an appropriate therapeutic regimen to be instituted. More advanced or refractory cases need to be identified, allowing for an appropriate dermatologist referral when necessary.
[Mh] Termos MeSH primário: Alopecia em Áreas/tratamento farmacológico
Fármacos Dermatológicos/uso terapêutico
Imunossupressores/uso terapêutico
Atenção Primária à Saúde/métodos
Encaminhamento e Consulta
[Mh] Termos MeSH secundário: Adulto
Alopecia em Áreas/psicologia
Antralina
Criança
Ciclopropanos/uso terapêutico
Seres Humanos
Esteroides/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cyclopropanes); 0 (Dermatologic Agents); 0 (Immunosuppressive Agents); 0 (Steroids); I7G14NW5EC (diphenylcyclopropenone); U8CJK0JH5M (Anthralin)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150916
[St] Status:MEDLINE



página 1 de 90 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde